MedTrace Logo

Improving Glycemic Control in DM2 Patients in the Ambulatory Setting

NCT04800471 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-02-10

Study results available
· View outcomes & findings →

Summary

More than 10.5% of the US population has diabetes mellitus. The objective of this pilot study is to evaluate whether smart insulin pens combined with CGM devices can improve glucose control in patients with type 2 diabetes (T2D)

Conditions

Interventions

DEVICE

Smart insulin pens and CGM

Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices

OTHER

Point of Care Glucose Group

Participants in this group will be monitored by POC glucose values.

Sponsors & Collaborators

  • University of Maryland, Baltimore

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-16
Primary Completion
2024-07-09
Completion
2024-07-09
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04800471 on ClinicalTrials.gov